Pulse Biosciences (PLSE) Non-Current Debt (2021 - 2023)
Pulse Biosciences' (PLSE) quarterly Non-Current Debt came in at $65.0 million in Q1 2023, little changed quarter-over-quarter from $65.0 million in Q4 2022.
Pulse Biosciences (PLSE) Non-Current Debt (2021 - 2023) Analysis & Trends
Pulse Biosciences' Non-Current Debt history runs 3 years deep, the most recent figure standing at $65.0 million for Q1 2023.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $65.0 million in Q1 2023; TTM through Mar 2023 was $65.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $65.0 million, changed N/A from the prior year.
- Non-Current Debt held at $65.0 million in Q1 2023 per PLSE's latest filing, from $65.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $65.0 million in Q3 2022 and bottomed at $41.0 million in Q1 2021.
- The 3-year median for Non-Current Debt is $65.0 million (2022), against an average of $59.0 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 4.16 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | - |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 14.71 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 12.50 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 404.17 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 202.90 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 1.86 Bn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 4.58 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | - |
| 10 | Pulse Biosciences | 2.09 Bn | 2.01 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 65.00 Mn |
| Dec 31, 2022 | 65.00 Mn |
| Sep 30, 2022 | 65.00 Mn |
| Mar 31, 2021 | 41.00 Mn |